000			01761 a2200469 4500
005			20250515233047.0
264		0	_c20110106
008			201101s 0 0 fre d
022			_a1769-664X
024	7		_a10.1016/S0929-693X(10)70199-8 _2doi
040			_aNLM _beng _cNLM
100	1		_aBader-Meunier, B
245	0	0	_a[Tolerance of biological agents in children]. _h[electronic resource]
260			_bArchives de pediatrie : organe officiel de la Societe francaise de pediatrie _cJun 2010
300			_a962-3 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAbnormalities, Drug-Induced _xetiology
650	0	4	_aAdalimumab
650	0	4	_aAdolescent
650	0	4	_aAdverse Drug Reaction Reporting Systems
650	0	4	_aAntibodies, Monoclonal _xadverse effects
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aAntibodies, Monoclonal, Murine-Derived _xadverse effects
650	0	4	_aArthritis, Juvenile _xdrug therapy
650	0	4	_aBiological Products _xadverse effects
650	0	4	_aChild
650	0	4	_aEtanercept
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aImmunoglobulin G _xadverse effects
650	0	4	_aInfant, Newborn
650	0	4	_aInflammatory Bowel Diseases _xdrug therapy
650	0	4	_aInfliximab
650	0	4	_aPregnancy
650	0	4	_aPsoriasis _xdrug therapy
650	0	4	_aReceptors, Tumor Necrosis Factor _xtherapeutic use
650	0	4	_aRisk
650	0	4	_aRituximab
650	0	4	_aTumor Necrosis Factor-alpha _xantagonists & inhibitors
773	0		_tArchives de pediatrie : organe officiel de la Societe francaise de pediatrie _gvol. 17 _gno. 6 _gp. 962-3
856	4	0	_uhttps://doi.org/10.1016/S0929-693X(10)70199-8 _zAvailable from publisher's website
999			_c19995383 _d19995383